Compare SRFM & MBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRFM | MBOT |
|---|---|---|
| Founded | 2011 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.3M | 145.7M |
| IPO Year | 2023 | 2000 |
| Metric | SRFM | MBOT |
|---|---|---|
| Price | $1.46 | $2.76 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $3.25 | ★ $7.50 |
| AVG Volume (30 Days) | ★ 1.9M | 1.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.69 | 30.48 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $106,557,000.00 | $116,887.00 |
| Revenue This Year | $10.33 | N/A |
| Revenue Next Year | $66.62 | $4,200.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.36 | $1.35 |
| 52 Week High | $9.35 | $4.62 |
| Indicator | SRFM | MBOT |
|---|---|---|
| Relative Strength Index (RSI) | 28.02 | 66.38 |
| Support Level | N/A | $2.34 |
| Resistance Level | $2.21 | $3.13 |
| Average True Range (ATR) | 0.15 | 0.15 |
| MACD | -0.04 | 0.03 |
| Stochastic Oscillator | 11.39 | 85.75 |
Surf Air Mobility Inc provides a regional air mobility platform to connect communities sustainably. The company is an electric aviation and air travel company expanding the category of regional air travel and reinventing flying through electrification. The company is building a regional air mobility ecosystem to sustainably connect the world's communities. It generates revenue through air mobility services.
Microbot Medical Inc is a breakthrough medical device company. The group is focused on transforming endovascular procedures through advanced robotic technology. Microbot's LIBERTY Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and provider safety. With a robust intellectual property portfolio and a deep commitment to innovation, Microbot is shaping the future of endovascular care.